Study characteristics and patient demographics of studies included in the network meta-analysis
| Study name . | Major chemotherapy regimen . | NK1RA . | 5HT3RA . | DEX . | N (male/female) . | Carboplatin-based regimen (%) . | CR-DP . | NN-DP . |
|---|---|---|---|---|---|---|---|---|
| Aridome_2016 | Oxaliplatin-based | APR | Any 5HT3RA | 3-day | 59 (34/25) | 0 | 47/59 | 38/59 |
| — | Any 5HT3RA | 3-day | 54 (30/24) | 0 | 43/54 | 37/54 | ||
| Celio_2011 | Carboplatin-based Oxaliplatin-based Irinotecan-based | — | Palo | 3-day | 100 | 16 (16.0) | 76/100 | NA |
| — | Palo | 1-day | 111 | 21 (18.9) | 79/111 | NA | ||
| Furukawa_2015 | Carboplatin-based | — | Palo | 3-day | 39 (0/39) | 39 (100) | 30/39 | 25/39 |
| — | Palo | 1-day | 43 (0/43) | 43 (100) | 30/43 | 26/43 | ||
| Ito_2014 | Carboplatin-based | APR | First-generation 5HT3RA day 1 | 3-day | 67 (56/11) | 67 (100) | 54/66 | 35/66 |
| — | First-generation 5HT3RA day 1 | 3-day | 67 (54/13) | 67 (100) | 46/67 | 29/67 | ||
| Kaushal_2015 | Carboplatin-based | APR | Palo | 3-day | 30 (29/1) | 30 (100) | 25/30 | 23/30 |
| — | OND day 1-3 | 3-day | 30 (23/7) | 30 (100) | 16/30 | 13/30 | ||
| Kim_2017 | Carboplatin-based Oxaliplatin-based Irinotecan-based | APR | OND day 1 | 1-day | 237 (129/108) | 156 (65.8) | 176/237 | NA |
| — | OND day 1-3 | 1-day | 243 (134/109) | 156 (64.2) | 173/243 | NA | ||
| Komatsu_2015 | Oxaliplatin-based Irinotecan-based | — | Palo | 3-day | 154 (87/67) | 19 (12.3) | 100/154 | NA |
| — | Palo | 1-day | 151 (86/65) | 18 (11.9) | 101/151 | NA | ||
| Kusagaya_2015 | Carboplatin-based | APR | Palo | 3-day | 41 (29/12) | 41 (100) | 33/41 | NA |
| — | Palo | 3-day | 39 (28/11) | 39 (100) | 30/39 | NA | ||
| Maehara_2015 | Carboplatin-based | APR | GRA day 1 | 3-day | 11 (0/11) | 11 (100) | 11/11 | 10/11 |
| — | GRN day 1 | 3-day | 12 (0/12) | 12 (100) | 8/12 | 2/12 | ||
| Matsuura_2015 | Carboplatin-based | — | Palo | 3-day | 53 (0/53) | 53 (100) | 36/53 | NA |
| — | Palo | 1-day | 56 (0/56) | 56 (100) | 34/56 | NA | ||
| Nishimura_2015 | Oxaliplatin-based | APR | 5HT3RA day 1 | 3-day | 207 (126/81) | 0 | 159/187 | 124/187 |
| — | 5HT3RA day 1 | 3-day | 206 (126/80) | 0 | 138/183 | 113/183 | ||
| Rapoport_2010 | Carboplatin-based Irinotecan-based Oxaliplatin-based Other non-AC MEC | APR | OND day 1 | 1-day | 226 | NAa | 172/226 | NA |
| — | OND day 1-3 | 1-day | 203 | NAa | 140/203 | NA | ||
| Schwartzberg_2015 | Carboplatin-based Irinotecan-based Oxaliplatin-based Other non-AC MEC | ROL | GRN day 1-3 | 1-day | 322 | 191 (59.3) | 245/322 | NA |
| — | GRN day 1-3 | 1-day | 307 | 209 (68.1) | 196/307 | NA | ||
| Sugimori_2017 | Carboplatin-based | APR | Palo | 3-day | 39 (0/39) | 39 (100) | 38/39 | 27/39 |
| — | Palo | 3-day | 39 (0/39) | 39 (100) | 32/39 | 25/39 | ||
| Tanioka_2013 | Carboplatin-based | APR | GRN day 1 | 3-day | 45 (0/45) | 44 (97.8) | 28/45 | NA |
| — | GRN day 1 | 3-day | 46 (0/46) | 45 (97.8) | 24/46 | NA | ||
| Weinstein_2016 | Carboplatin-based Oxaliplatin-based | FAPR | OND day 1 | 1-day | 502 (204/298) | 257 (51.2) | 396/502 | NA |
| — | OND day 1-3 | 1-day | 498 (205/293) | 256 (51.4) | 341/498 | NA | ||
| Yahata_2016 | Carboplatin-based | APR | First-generation 5HT3RA day 1 | 1-day | 155 (0/155) | 155 (100) | 96/151 | 61/151 |
| — | First-generation 5HT3RA day 1 | 1-day | 152 (0/152) | 152 (100) | 72/146 | 49/146 |
| Study name . | Major chemotherapy regimen . | NK1RA . | 5HT3RA . | DEX . | N (male/female) . | Carboplatin-based regimen (%) . | CR-DP . | NN-DP . |
|---|---|---|---|---|---|---|---|---|
| Aridome_2016 | Oxaliplatin-based | APR | Any 5HT3RA | 3-day | 59 (34/25) | 0 | 47/59 | 38/59 |
| — | Any 5HT3RA | 3-day | 54 (30/24) | 0 | 43/54 | 37/54 | ||
| Celio_2011 | Carboplatin-based Oxaliplatin-based Irinotecan-based | — | Palo | 3-day | 100 | 16 (16.0) | 76/100 | NA |
| — | Palo | 1-day | 111 | 21 (18.9) | 79/111 | NA | ||
| Furukawa_2015 | Carboplatin-based | — | Palo | 3-day | 39 (0/39) | 39 (100) | 30/39 | 25/39 |
| — | Palo | 1-day | 43 (0/43) | 43 (100) | 30/43 | 26/43 | ||
| Ito_2014 | Carboplatin-based | APR | First-generation 5HT3RA day 1 | 3-day | 67 (56/11) | 67 (100) | 54/66 | 35/66 |
| — | First-generation 5HT3RA day 1 | 3-day | 67 (54/13) | 67 (100) | 46/67 | 29/67 | ||
| Kaushal_2015 | Carboplatin-based | APR | Palo | 3-day | 30 (29/1) | 30 (100) | 25/30 | 23/30 |
| — | OND day 1-3 | 3-day | 30 (23/7) | 30 (100) | 16/30 | 13/30 | ||
| Kim_2017 | Carboplatin-based Oxaliplatin-based Irinotecan-based | APR | OND day 1 | 1-day | 237 (129/108) | 156 (65.8) | 176/237 | NA |
| — | OND day 1-3 | 1-day | 243 (134/109) | 156 (64.2) | 173/243 | NA | ||
| Komatsu_2015 | Oxaliplatin-based Irinotecan-based | — | Palo | 3-day | 154 (87/67) | 19 (12.3) | 100/154 | NA |
| — | Palo | 1-day | 151 (86/65) | 18 (11.9) | 101/151 | NA | ||
| Kusagaya_2015 | Carboplatin-based | APR | Palo | 3-day | 41 (29/12) | 41 (100) | 33/41 | NA |
| — | Palo | 3-day | 39 (28/11) | 39 (100) | 30/39 | NA | ||
| Maehara_2015 | Carboplatin-based | APR | GRA day 1 | 3-day | 11 (0/11) | 11 (100) | 11/11 | 10/11 |
| — | GRN day 1 | 3-day | 12 (0/12) | 12 (100) | 8/12 | 2/12 | ||
| Matsuura_2015 | Carboplatin-based | — | Palo | 3-day | 53 (0/53) | 53 (100) | 36/53 | NA |
| — | Palo | 1-day | 56 (0/56) | 56 (100) | 34/56 | NA | ||
| Nishimura_2015 | Oxaliplatin-based | APR | 5HT3RA day 1 | 3-day | 207 (126/81) | 0 | 159/187 | 124/187 |
| — | 5HT3RA day 1 | 3-day | 206 (126/80) | 0 | 138/183 | 113/183 | ||
| Rapoport_2010 | Carboplatin-based Irinotecan-based Oxaliplatin-based Other non-AC MEC | APR | OND day 1 | 1-day | 226 | NAa | 172/226 | NA |
| — | OND day 1-3 | 1-day | 203 | NAa | 140/203 | NA | ||
| Schwartzberg_2015 | Carboplatin-based Irinotecan-based Oxaliplatin-based Other non-AC MEC | ROL | GRN day 1-3 | 1-day | 322 | 191 (59.3) | 245/322 | NA |
| — | GRN day 1-3 | 1-day | 307 | 209 (68.1) | 196/307 | NA | ||
| Sugimori_2017 | Carboplatin-based | APR | Palo | 3-day | 39 (0/39) | 39 (100) | 38/39 | 27/39 |
| — | Palo | 3-day | 39 (0/39) | 39 (100) | 32/39 | 25/39 | ||
| Tanioka_2013 | Carboplatin-based | APR | GRN day 1 | 3-day | 45 (0/45) | 44 (97.8) | 28/45 | NA |
| — | GRN day 1 | 3-day | 46 (0/46) | 45 (97.8) | 24/46 | NA | ||
| Weinstein_2016 | Carboplatin-based Oxaliplatin-based | FAPR | OND day 1 | 1-day | 502 (204/298) | 257 (51.2) | 396/502 | NA |
| — | OND day 1-3 | 1-day | 498 (205/293) | 256 (51.4) | 341/498 | NA | ||
| Yahata_2016 | Carboplatin-based | APR | First-generation 5HT3RA day 1 | 1-day | 155 (0/155) | 155 (100) | 96/151 | 61/151 |
| — | First-generation 5HT3RA day 1 | 1-day | 152 (0/152) | 152 (100) | 72/146 | 49/146 |
Data could not be extracted from among the other chemotherapy regimens.
Abbreviations: 5HT3RA, serotonin receptor antagonist; APR, aprepitant; CR-DP, complete response during delayed phase; DEX, dexamethasone; FAPR, fos-aprepitant; GRN, granisetron; NA, not available; NK1RA, neurokinin-1 receptor antagonist; NN-DP, no nausea during delayed phase; OND, ondansetron; Palo, palonosetron; ROL, rolapitant.
Study characteristics and patient demographics of studies included in the network meta-analysis
| Study name . | Major chemotherapy regimen . | NK1RA . | 5HT3RA . | DEX . | N (male/female) . | Carboplatin-based regimen (%) . | CR-DP . | NN-DP . |
|---|---|---|---|---|---|---|---|---|
| Aridome_2016 | Oxaliplatin-based | APR | Any 5HT3RA | 3-day | 59 (34/25) | 0 | 47/59 | 38/59 |
| — | Any 5HT3RA | 3-day | 54 (30/24) | 0 | 43/54 | 37/54 | ||
| Celio_2011 | Carboplatin-based Oxaliplatin-based Irinotecan-based | — | Palo | 3-day | 100 | 16 (16.0) | 76/100 | NA |
| — | Palo | 1-day | 111 | 21 (18.9) | 79/111 | NA | ||
| Furukawa_2015 | Carboplatin-based | — | Palo | 3-day | 39 (0/39) | 39 (100) | 30/39 | 25/39 |
| — | Palo | 1-day | 43 (0/43) | 43 (100) | 30/43 | 26/43 | ||
| Ito_2014 | Carboplatin-based | APR | First-generation 5HT3RA day 1 | 3-day | 67 (56/11) | 67 (100) | 54/66 | 35/66 |
| — | First-generation 5HT3RA day 1 | 3-day | 67 (54/13) | 67 (100) | 46/67 | 29/67 | ||
| Kaushal_2015 | Carboplatin-based | APR | Palo | 3-day | 30 (29/1) | 30 (100) | 25/30 | 23/30 |
| — | OND day 1-3 | 3-day | 30 (23/7) | 30 (100) | 16/30 | 13/30 | ||
| Kim_2017 | Carboplatin-based Oxaliplatin-based Irinotecan-based | APR | OND day 1 | 1-day | 237 (129/108) | 156 (65.8) | 176/237 | NA |
| — | OND day 1-3 | 1-day | 243 (134/109) | 156 (64.2) | 173/243 | NA | ||
| Komatsu_2015 | Oxaliplatin-based Irinotecan-based | — | Palo | 3-day | 154 (87/67) | 19 (12.3) | 100/154 | NA |
| — | Palo | 1-day | 151 (86/65) | 18 (11.9) | 101/151 | NA | ||
| Kusagaya_2015 | Carboplatin-based | APR | Palo | 3-day | 41 (29/12) | 41 (100) | 33/41 | NA |
| — | Palo | 3-day | 39 (28/11) | 39 (100) | 30/39 | NA | ||
| Maehara_2015 | Carboplatin-based | APR | GRA day 1 | 3-day | 11 (0/11) | 11 (100) | 11/11 | 10/11 |
| — | GRN day 1 | 3-day | 12 (0/12) | 12 (100) | 8/12 | 2/12 | ||
| Matsuura_2015 | Carboplatin-based | — | Palo | 3-day | 53 (0/53) | 53 (100) | 36/53 | NA |
| — | Palo | 1-day | 56 (0/56) | 56 (100) | 34/56 | NA | ||
| Nishimura_2015 | Oxaliplatin-based | APR | 5HT3RA day 1 | 3-day | 207 (126/81) | 0 | 159/187 | 124/187 |
| — | 5HT3RA day 1 | 3-day | 206 (126/80) | 0 | 138/183 | 113/183 | ||
| Rapoport_2010 | Carboplatin-based Irinotecan-based Oxaliplatin-based Other non-AC MEC | APR | OND day 1 | 1-day | 226 | NAa | 172/226 | NA |
| — | OND day 1-3 | 1-day | 203 | NAa | 140/203 | NA | ||
| Schwartzberg_2015 | Carboplatin-based Irinotecan-based Oxaliplatin-based Other non-AC MEC | ROL | GRN day 1-3 | 1-day | 322 | 191 (59.3) | 245/322 | NA |
| — | GRN day 1-3 | 1-day | 307 | 209 (68.1) | 196/307 | NA | ||
| Sugimori_2017 | Carboplatin-based | APR | Palo | 3-day | 39 (0/39) | 39 (100) | 38/39 | 27/39 |
| — | Palo | 3-day | 39 (0/39) | 39 (100) | 32/39 | 25/39 | ||
| Tanioka_2013 | Carboplatin-based | APR | GRN day 1 | 3-day | 45 (0/45) | 44 (97.8) | 28/45 | NA |
| — | GRN day 1 | 3-day | 46 (0/46) | 45 (97.8) | 24/46 | NA | ||
| Weinstein_2016 | Carboplatin-based Oxaliplatin-based | FAPR | OND day 1 | 1-day | 502 (204/298) | 257 (51.2) | 396/502 | NA |
| — | OND day 1-3 | 1-day | 498 (205/293) | 256 (51.4) | 341/498 | NA | ||
| Yahata_2016 | Carboplatin-based | APR | First-generation 5HT3RA day 1 | 1-day | 155 (0/155) | 155 (100) | 96/151 | 61/151 |
| — | First-generation 5HT3RA day 1 | 1-day | 152 (0/152) | 152 (100) | 72/146 | 49/146 |
| Study name . | Major chemotherapy regimen . | NK1RA . | 5HT3RA . | DEX . | N (male/female) . | Carboplatin-based regimen (%) . | CR-DP . | NN-DP . |
|---|---|---|---|---|---|---|---|---|
| Aridome_2016 | Oxaliplatin-based | APR | Any 5HT3RA | 3-day | 59 (34/25) | 0 | 47/59 | 38/59 |
| — | Any 5HT3RA | 3-day | 54 (30/24) | 0 | 43/54 | 37/54 | ||
| Celio_2011 | Carboplatin-based Oxaliplatin-based Irinotecan-based | — | Palo | 3-day | 100 | 16 (16.0) | 76/100 | NA |
| — | Palo | 1-day | 111 | 21 (18.9) | 79/111 | NA | ||
| Furukawa_2015 | Carboplatin-based | — | Palo | 3-day | 39 (0/39) | 39 (100) | 30/39 | 25/39 |
| — | Palo | 1-day | 43 (0/43) | 43 (100) | 30/43 | 26/43 | ||
| Ito_2014 | Carboplatin-based | APR | First-generation 5HT3RA day 1 | 3-day | 67 (56/11) | 67 (100) | 54/66 | 35/66 |
| — | First-generation 5HT3RA day 1 | 3-day | 67 (54/13) | 67 (100) | 46/67 | 29/67 | ||
| Kaushal_2015 | Carboplatin-based | APR | Palo | 3-day | 30 (29/1) | 30 (100) | 25/30 | 23/30 |
| — | OND day 1-3 | 3-day | 30 (23/7) | 30 (100) | 16/30 | 13/30 | ||
| Kim_2017 | Carboplatin-based Oxaliplatin-based Irinotecan-based | APR | OND day 1 | 1-day | 237 (129/108) | 156 (65.8) | 176/237 | NA |
| — | OND day 1-3 | 1-day | 243 (134/109) | 156 (64.2) | 173/243 | NA | ||
| Komatsu_2015 | Oxaliplatin-based Irinotecan-based | — | Palo | 3-day | 154 (87/67) | 19 (12.3) | 100/154 | NA |
| — | Palo | 1-day | 151 (86/65) | 18 (11.9) | 101/151 | NA | ||
| Kusagaya_2015 | Carboplatin-based | APR | Palo | 3-day | 41 (29/12) | 41 (100) | 33/41 | NA |
| — | Palo | 3-day | 39 (28/11) | 39 (100) | 30/39 | NA | ||
| Maehara_2015 | Carboplatin-based | APR | GRA day 1 | 3-day | 11 (0/11) | 11 (100) | 11/11 | 10/11 |
| — | GRN day 1 | 3-day | 12 (0/12) | 12 (100) | 8/12 | 2/12 | ||
| Matsuura_2015 | Carboplatin-based | — | Palo | 3-day | 53 (0/53) | 53 (100) | 36/53 | NA |
| — | Palo | 1-day | 56 (0/56) | 56 (100) | 34/56 | NA | ||
| Nishimura_2015 | Oxaliplatin-based | APR | 5HT3RA day 1 | 3-day | 207 (126/81) | 0 | 159/187 | 124/187 |
| — | 5HT3RA day 1 | 3-day | 206 (126/80) | 0 | 138/183 | 113/183 | ||
| Rapoport_2010 | Carboplatin-based Irinotecan-based Oxaliplatin-based Other non-AC MEC | APR | OND day 1 | 1-day | 226 | NAa | 172/226 | NA |
| — | OND day 1-3 | 1-day | 203 | NAa | 140/203 | NA | ||
| Schwartzberg_2015 | Carboplatin-based Irinotecan-based Oxaliplatin-based Other non-AC MEC | ROL | GRN day 1-3 | 1-day | 322 | 191 (59.3) | 245/322 | NA |
| — | GRN day 1-3 | 1-day | 307 | 209 (68.1) | 196/307 | NA | ||
| Sugimori_2017 | Carboplatin-based | APR | Palo | 3-day | 39 (0/39) | 39 (100) | 38/39 | 27/39 |
| — | Palo | 3-day | 39 (0/39) | 39 (100) | 32/39 | 25/39 | ||
| Tanioka_2013 | Carboplatin-based | APR | GRN day 1 | 3-day | 45 (0/45) | 44 (97.8) | 28/45 | NA |
| — | GRN day 1 | 3-day | 46 (0/46) | 45 (97.8) | 24/46 | NA | ||
| Weinstein_2016 | Carboplatin-based Oxaliplatin-based | FAPR | OND day 1 | 1-day | 502 (204/298) | 257 (51.2) | 396/502 | NA |
| — | OND day 1-3 | 1-day | 498 (205/293) | 256 (51.4) | 341/498 | NA | ||
| Yahata_2016 | Carboplatin-based | APR | First-generation 5HT3RA day 1 | 1-day | 155 (0/155) | 155 (100) | 96/151 | 61/151 |
| — | First-generation 5HT3RA day 1 | 1-day | 152 (0/152) | 152 (100) | 72/146 | 49/146 |
Data could not be extracted from among the other chemotherapy regimens.
Abbreviations: 5HT3RA, serotonin receptor antagonist; APR, aprepitant; CR-DP, complete response during delayed phase; DEX, dexamethasone; FAPR, fos-aprepitant; GRN, granisetron; NA, not available; NK1RA, neurokinin-1 receptor antagonist; NN-DP, no nausea during delayed phase; OND, ondansetron; Palo, palonosetron; ROL, rolapitant.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
